Last updated: September 9, 2026
AG-348, now marketed as Pyrukynd, is mitapivat, an oral pyruvate kinase activator developed by Agios Pharmaceuticals. The FDA approved it in February 2022 for hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited red-blood-cell disorder. Agios is expanding development into thalassemia and sickle cell disease, where the addressable population is materially larger than the approved PK-deficiency market.[1]
The commercial outlook depends on three factors: broader indications, sustained reimbursement for a rare-disease oral therapy, and the timing of generic entry after Orange Book patent protection expires. Under a successful thalassemia launch, mitapivat could support annual global revenue above $1 billion. Under a PK-deficiency-only scenario, annual sales are more likely to remain below $500 million.
What is the current FDA status of AG-348 and Pyrukynd?
Pyrukynd is FDA-approved for hemolytic anemia in adults with pyruvate kinase deficiency. The drug is administered orally twice daily, with dose titration based on response and tolerability.[1]
| Item |
Status |
| Active ingredient |
Mitapivat |
| Development code |
AG-348 |
| Brand |
Pyrukynd |
| Sponsor |
Agios Pharmaceuticals |
| FDA approval |
February 17, 2022 |
| Initial indication |
Hemolytic anemia in adults with pyruvate kinase deficiency |
| Regulatory pathway |
New drug application, NDA 216196 |
| Drug type |
Small-molecule allosteric pyruvate kinase activator |
| Biosimilar exposure |
None |
| Generic exposure |
Relevant after small-molecule patent and regulatory exclusivity periods |
The FDA approval was based principally on ACTIVATE, a randomized Phase 3 trial in adults with pyruvate kinase deficiency who were not regularly transfused. Pyrukynd produced a significantly higher hemoglobin response than placebo. ACTIVATE-T evaluated adults who required regular transfusions and showed a reduction in transfusion burden.[2]
How does mitapivat work?
Mitapivat activates red-blood-cell pyruvate kinase, primarily PKR, an enzyme involved in glycolysis. PKR activation increases ATP production in red blood cells. The mechanism can improve red-cell survival and reduce hemolysis.
The mechanism is relevant beyond PK deficiency. Thalassemia and sickle cell disease involve red-cell stress, ineffective erythropoiesis, anemia, or hemolysis. Mitapivat is being evaluated as a disease-modifying oral therapy rather than as a transfusion-only or supportive-care product.
The principal clinical risks are dose tolerability, loss of response, drug interactions, and the need to establish benefit across genetically and clinically diverse patient populations.
What are the latest development programs for mitapivat?
Thalassemia
Agios has conducted separate Phase 3 studies in non-transfusion-dependent and regularly transfused thalassemia.
The ENERGIZE study evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia. The ENERGIZE-T study evaluated adults with transfusion-dependent thalassemia. Agios reported positive topline results from both studies in 2024, including improvements in hemoglobin response or transfusion reduction, depending on the trial population.[3]
A successful thalassemia filing would expand the market from a very rare PK-deficiency population to a broader inherited-anemia population. The commercial opportunity is strongest in beta-thalassemia, where chronic transfusion, iron overload, chelation therapy, and luspatercept use create a substantial treatment market.
Sickle cell disease
Agios has studied mitapivat in sickle cell disease through the RISE UP program. The program includes adults and adolescents with sickle cell disease and is designed to assess anemia, hemolysis, vaso-occlusive events, and other clinical outcomes.
Sickle cell disease represents the largest potential indication by patient count. It also presents the highest development risk. The competitive market includes hydroxyurea, voxelotor, crizanlizumab, L-glutamine, transfusion, hematopoietic stem-cell transplantation, and emerging gene therapies. Voxelotor's 2024 withdrawal from the market changed the competitive environment, but it did not eliminate the need for robust clinical evidence in sickle cell disease.[4]
Development timeline
| Period |
Event |
| 2019 |
ACTIVATE and ACTIVATE-T Phase 3 data reported |
| 2022 |
FDA approved Pyrukynd for adult PK deficiency |
| 2022 |
European Commission authorization for PK deficiency |
| 2023-2024 |
Expansion studies in thalassemia and sickle cell disease |
| 2024 |
Positive topline Phase 3 thalassemia results reported |
| 2024 onward |
Regulatory preparation and continued sickle-cell development |
Regulatory timing for thalassemia depends on the completeness of the filing package, FDA review designation, and the agency's assessment of the clinical data. A thalassemia approval could occur before a sickle-cell approval because the thalassemia Phase 3 program has generated more mature late-stage evidence.
How large is the mitapivat market?
The approved PK-deficiency population is small. Published estimates generally place global PK-deficiency prevalence in the low thousands, although diagnosis rates are incomplete and vary by geography.[5]
A market model based on diagnosed and treated patients produces the following range:
| Scenario |
Treated population |
Annual net price assumption |
Potential annual revenue |
| PK deficiency only |
1,000-2,500 |
$150,000-$220,000 |
$150 million-$550 million |
| PK deficiency plus thalassemia |
5,000-12,000 |
$100,000-$180,000 |
$500 million-$1.8 billion |
| Broad thalassemia adoption |
10,000-20,000 |
$90,000-$160,000 |
$900 million-$3.2 billion |
| Sickle-cell expansion |
20,000-50,000 incremental patients |
$50,000-$120,000 |
$1 billion-$6 billion incremental |
These figures are addressable-market estimates, not reported company guidance. Actual net revenue would be reduced by rebates, government pricing, patient assistance, treatment discontinuation, international pricing, and restrictions from payers.
The most defensible base case is annual global sales of $500 million to $1.2 billion if thalassemia approval is achieved and commercial uptake is sustained. The upper case requires meaningful penetration in sickle cell disease and a price that payers accept relative to existing disease-modifying therapies.
What is the commercial performance of Pyrukynd?
Agios reported rapid early adoption after the 2022 launch, but the product started from a small diagnosed population. Commercial growth depends on finding undiagnosed PK-deficiency patients, increasing genetic testing, and moving eligible patients from transfusion or supportive management to chronic oral treatment.
Key commercial constraints include:
- Low disease prevalence in the current indication.
- Limited specialist prescriber base.
- Need for genetic or enzyme-based diagnosis.
- Chronic dosing and dose titration.
- Potential payer controls for rare-disease therapies.
- Competition from transfusion, chelation, and disease-specific therapies in expanded indications.
Thalassemia offers a clearer commercial path than PK deficiency because patient identification is more established and treatment centers are concentrated. Sickle cell disease offers the greatest volume but also the most complex competitive and clinical environment.
What patents protect mitapivat and Pyrukynd?
Mitapivat is protected by composition-of-matter, pharmaceutical-composition, dosing, and method-of-use patent families. The relevant patent estate originated with Agios and covers substituted pyrazine compounds and their use as pyruvate kinase activators.
The earliest core U.S. composition patent is commonly identified as U.S. Patent No. 9,266,858, with patent-term calculations generally extending into the late 2020s or early 2030s depending on the specific patent and any patent-term adjustment. Later patents may cover dosing regimens, formulations, and treatment of specific diseases.
| Protection category |
Commercial relevance |
| Composition of matter |
Primary barrier to generic mitapivat |
| Pharmaceutical composition |
May protect tablets, excipients, or dosage forms |
| Dose escalation and administration |
May delay label-based generic substitution |
| PK deficiency methods |
Protects the approved use |
| Thalassemia methods |
Could support indication-specific enforcement |
| Sickle-cell methods |
Potential later-expiring use protection |
| Regulatory exclusivity |
Provides protection independent of patents |
The precise Orange Book listing and expiration date must be assessed patent by patent. Patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and litigation settlements can materially change the effective generic-entry date. FDA Orange Book records are the controlling source for listed patents and exclusivity status.[6]
What is the Orange Book status of Pyrukynd?
Pyrukynd is listed in the FDA Orange Book under NDA 216196. It is a small-molecule product, so it is exposed to an abbreviated new drug application, or ANDA, pathway rather than a biosimilar pathway.
A generic applicant may file a Paragraph IV certification alleging that an Orange Book patent is invalid, unenforceable, or not infringed. If the patent holder sues within the statutory period, FDA approval can be stayed for up to 30 months, subject to court action and statutory exceptions.[7]
There was no widely reported market-shaping Paragraph IV litigation against Pyrukynd through mid-2024. The absence of a public challenge at that stage does not eliminate future risk. Paragraph IV filings typically become more likely as core patent expiration approaches and the commercial opportunity becomes large enough to justify litigation costs.
When could generic mitapivat enter the market?
The earliest practical generic-entry date depends on the strongest enforceable composition patent, any patent-term extension, regulatory exclusivity, and litigation outcomes.
A reasonable scenario range is:
| Scenario |
Potential entry timing |
Conditions |
| Early challenge |
Late 2020s |
Successful Paragraph IV challenge or noninfringement outcome |
| Base case |
Early-to-mid 2030s |
Core patents remain enforceable until listed expiry |
| Delayed entry |
Mid-2030s or later |
Later method, formulation, or pediatric protection and successful litigation |
Generic erosion would likely be gradual in PK deficiency because the patient population is small and treatment is specialist-managed. Erosion could be faster after a thalassemia approval because the market would support more generic competition.
Which companies compete with mitapivat?
Mitapivat has no approved direct PK activator competitor in the United States as of mid-2024. Its broader competitive set varies by indication.
| Indication |
Main alternatives |
| PK deficiency |
Transfusion, splenectomy in selected patients, supportive care |
| Beta-thalassemia |
Luspatercept, transfusion, iron chelation, stem-cell transplantation |
| Sickle cell disease |
Hydroxyurea, crizanlizumab, L-glutamine, transfusion, gene therapies |
| Hemolytic anemia |
Disease-specific immunosuppression or supportive therapy, depending on cause |
Luspatercept is the most important commercial comparator in thalassemia. It is injectable and acts primarily through erythroid maturation, while mitapivat is an oral metabolic therapy. Their use may be competitive, sequential, or complementary depending on label, payer policy, and clinical response.
What licensing and corporate transactions affect mitapivat?
Agios retained rights to mitapivat after selling its oncology business to Servier in 2020. The Servier transaction did not transfer Pyrukynd's core commercial program. Agios therefore retains the principal economic exposure to U.S. mitapivat sales and to successful expansion into hematologic diseases.[8]
The company could pursue regional partnerships for commercialization, but a large transaction is not required for the base-case model because Agios has an established rare-disease commercial infrastructure.
How strong is the mitapivat patent and market position?
The patent position is strongest for the original molecule and weaker for later indication-specific claims. A composition patent provides broader protection than a method-of-use patent because a generic may face infringement risk even if it markets a narrower label.
The commercial position is strongest in PK deficiency because Pyrukynd is the first approved therapy specifically targeting the underlying red-cell metabolic defect. The position is less secure in thalassemia and sickle cell disease because treatment guidelines, competing mechanisms, and payer restrictions will determine adoption.
The main value inflection point is a thalassemia approval. Sickle-cell data would increase the long-term ceiling but also expose the product to a more competitive market and a higher evidentiary burden.
Key Takeaways
- AG-348 is mitapivat, marketed in the United States as Pyrukynd.
- FDA approval covers hemolytic anemia in adults with pyruvate kinase deficiency.
- Thalassemia is the most commercially advanced expansion opportunity.
- Sickle cell disease is the largest potential market but carries greater development and competitive risk.
- A reasonable base-case peak-sales range is $500 million to $1.2 billion globally after a successful thalassemia expansion.
- Generic entry is unlikely to be commercially meaningful before the late 2020s and may occur in the early-to-mid 2030s, depending on patent litigation and Orange Book protection.
- There is no biosimilar pathway because mitapivat is a small molecule.
- Agios retains the principal economic rights to the mitapivat program.
FAQs
Is AG-348 the same drug as Pyrukynd?
Yes. AG-348 is the development code for mitapivat, and Pyrukynd is the commercial brand name.
Is mitapivat approved for thalassemia?
The initial FDA approval was for pyruvate kinase deficiency. Thalassemia approval depends on regulatory review of the Phase 3 ENERGIZE and ENERGIZE-T data.
Does mitapivat compete with luspatercept?
Yes, in thalassemia. Mitapivat is an oral pyruvate kinase activator, while luspatercept is an injectable erythroid-maturation agent. Their relative positioning will depend on indication-specific labels and clinical outcomes.
Can a generic company file an ANDA for Pyrukynd?
Yes. Mitapivat is a small molecule, so generic applicants can use the ANDA pathway and challenge listed patents through Paragraph IV certifications.
What is the biggest risk to the mitapivat market forecast?
The largest risk is failure to convert positive development data into broad regulatory approval and payer coverage in thalassemia or sickle cell disease. The PK-deficiency market alone is unlikely to support the highest revenue projections.
References
- U.S. Food and Drug Administration. (2022). FDA approves first drug for anemia in adults with rare inherited blood disorder. https://www.fda.gov
- Glenthøj, A., et al. (2022). Mitapivat versus placebo for pyruvate kinase deficiency. New England Journal of Medicine, 386, 1432-1442.
- Agios Pharmaceuticals, Inc. (2024). Agios announces positive topline results from Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. https://investor.agios.com
- Pfizer Inc. (2024). Pfizer provides update on Oxbryta manufacturing and global voluntary withdrawal. https://www.pfizer.com
- Grace, R. F., et al. (2015). The clinical spectrum of pyruvate kinase deficiency: Data from the PK deficiency natural history study. Blood, 126(15), 1772-1779.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
- Agios Pharmaceuticals, Inc. (2020). Agios and Servier announce closing of transaction for Agios’ oncology business. https://investor.agios.com